Crinetics Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Crinetics Pharmaceuticals, Inc. (CRNX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $46.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-03-31 was $4.10M, a 70.29% decline year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-12-31 was $17.90M, a 80.81% increase year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-09-30 was $20.20M, a 267.27% increase year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2024-06-30 was $20.20M, a 2785.71% increase year-over-year.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $46.50M, a 35.51% decline from fiscal 2024.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $72.10M, a 345.06% increase from fiscal 2023.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $16.20M, a 174.58% increase from fiscal 2022.
- Crinetics Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $5.90M, a 15.69% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $46.50M 10-K · filed 2026-02-26 | ||||
| 2025-03-31 | $4.10M 10-Q · filed 2025-05-08 | $22.00M derived: sum of 2 quarters · filed 2026-02-26 | $42.20M derived: sum of 3 quarters · filed 2026-02-26 | $62.40M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | $17.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $38.10M derived: sum of 2 quarters · filed 2026-02-26 | $58.30M derived: sum of 3 quarters · filed 2026-02-26 | $72.10M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $20.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $40.40M derived: sum of 2 quarters · filed 2024-11-12 | $54.20M 10-Q · filed 2024-11-12 | $64.10M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $20.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $34.00M 10-Q · filed 2024-08-08 | $43.90M derived: sum of 3 quarters · filed 2026-02-26 | $49.40M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $13.80M 10-Q · filed 2025-05-08 | $23.70M derived: sum of 2 quarters · filed 2026-02-26 | $29.20M derived: sum of 3 quarters · filed 2026-02-26 | $29.90M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $9.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $15.40M derived: sum of 2 quarters · filed 2026-02-26 | $16.10M derived: sum of 3 quarters · filed 2026-02-26 | $16.20M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $5.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $6.20M derived: sum of 2 quarters · filed 2024-11-12 | $6.30M 10-Q · filed 2024-11-12 | $6.60M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $800.00K 10-Q · filed 2024-08-08 | $1.10M derived: sum of 3 quarters · filed 2025-02-27 | $1.60M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-09 | $400.00K derived: sum of 2 quarters · filed 2025-02-27 | $900.00K derived: sum of 3 quarters · filed 2025-02-27 | $3.80M derived: sum of 4 quarters · filed 2025-02-27 | |
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $800.00K derived: sum of 2 quarters · filed 2025-02-27 | $3.70M derived: sum of 3 quarters · filed 2025-02-27 | $5.90M 10-K · filed 2025-02-27 | |
| 2022-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.40M derived: sum of 2 quarters · filed 2023-11-07 | $5.60M 10-Q · filed 2023-11-07 | $9.10M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-06-30 | $2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $5.10M 10-Q · filed 2023-08-08 | $8.60M derived: sum of 3 quarters · filed 2024-02-28 | $9.80M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2022-03-31 | $2.20M 10-Q · filed 2023-05-09 | $5.70M derived: sum of 2 quarters · filed 2024-02-28 | $6.90M derived: sum of 3 quarters · filed 2024-02-28 | $7.20M derived: sum of 4 quarters · filed 2024-02-28 | |
| 2021-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $4.70M derived: sum of 2 quarters · filed 2024-02-28 | $5.00M derived: sum of 3 quarters · filed 2024-02-28 | $5.10M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $1.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $1.50M derived: sum of 2 quarters · filed 2021-11-05 | $1.60M 10-Q · filed 2021-11-05 | $2.10M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $400.00K 10-Q · filed 2021-08-10 | $900.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.40M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $100.00K 10-Q · filed 2021-05-06 | $600.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.10M derived: sum of 3 quarters · filed 2023-02-28 | $1.70M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $1.00M derived: sum of 2 quarters · filed 2023-02-28 | $1.60M derived: sum of 3 quarters · filed 2023-02-28 | $2.50M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $500.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $1.10M derived: sum of 2 quarters · filed 2020-11-06 | $2.00M 10-Q · filed 2020-11-06 | $2.30M derived: sum of 4 quarters · filed 2022-03-30 | |
| 2020-06-30 | $600.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $1.50M 10-Q · filed 2020-08-07 | $1.80M derived: sum of 3 quarters · filed 2022-03-30 | $2.00M derived: sum of 4 quarters · filed 2022-03-30 | |
| 2020-03-31 | $900.00K 10-Q · filed 2020-05-08 | $1.20M derived: sum of 2 quarters · filed 2022-03-30 | $1.40M derived: sum of 3 quarters · filed 2022-03-30 | $2.39M derived: sum of 4 quarters · filed 2022-03-30 | |
| 2019-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $500.00K derived: sum of 2 quarters · filed 2022-03-30 | $1.49M derived: sum of 3 quarters · filed 2022-03-30 | $2.00M 10-K · filed 2022-03-30 | |
| 2019-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $1.19M derived: sum of 2 quarters · filed 2019-11-12 | $1.70M 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $994.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $1.50M 10-Q · filed 2019-08-13 | |||
| 2019-03-31 | $506.00K 10-Q · filed 2019-05-13 | ||||
| 2018-12-31 | $2.40M 10-K · filed 2021-03-30 | $2.40M 10-K · filed 2019-03-13 |